Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pooling saliva to increase SARS-CoV-2 testing capacity

Anne E. Watkins, Eli P. Fenichel, Daniel M. Weinberger, Chantal B.F. Vogels, Doug E. Brackney, Arnau Casanovas-Massana, Melissa Campbell, John Fournier, Santos Bermejo, Rupak Datta, the Yale IMPACT Research Team, Charles S. Dela Cruz, Shelli F. Farhadian, Akiko Iwasaki, Albert I. Ko, Nathan D. Grubaugh, View ORCID ProfileAnne L. Wyllie
doi: https://doi.org/10.1101/2020.09.02.20183830
Anne E. Watkins
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eli P. Fenichel
2Yale School of the Environment, Yale University, New Haven, CT 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel M. Weinberger
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal B.F. Vogels
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doug E. Brackney
3Center for Vector-Borne and Zoonotic Diseases, Department of Environmental Sciences, The Connecticut Agricultural Experiment Station, New Haven, Connecticut 06504, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnau Casanovas-Massana
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Campbell
4Department of Pediatrics, Division of Infectious Diseases, Yale School of Medicine, New Haven, CT, 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Fournier
5Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santos Bermejo
6Department of Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT, 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rupak Datta
5Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles S. Dela Cruz
6Department of Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT, 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shelli F. Farhadian
5Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akiko Iwasaki
7Department of Immunobiology, Yale School of Medicine, New Haven, CT, 06510, USA
8Howard Hughes Medical Institute, New Haven, CT 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert I. Ko
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA
5Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan D. Grubaugh
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne L. Wyllie
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne L. Wyllie
  • For correspondence: eli.fenichel@yale.edu anne.wyllie@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Expanding testing capabilities is integral to managing the further spread of SARS-CoV-2 and developing reopening strategies, particularly in regards to identifying and isolating asymptomatic and pre-symptomatic individuals. Central to meeting testing demands are specimens that can be easily and reliably collected and laboratory capacity to rapidly ramp up to scale. We and others have demonstrated that high and consistent levels of SARS-CoV-2 RNA can be detected in saliva from COVID-19 inpatients, outpatients, and asymptomatic individuals. As saliva collection is non-invasive, extending this strategy to test pooled saliva samples from multiple individuals could thus provide a simple method to expand testing capacity.

However, hesitation towards pooled sample testing arises due to the dilution of positive samples, potentially shifting weakly positive samples below the detection limit for SARS-CoV-2 and thereby decreasing the sensitivity. Here, we investigated the potential of pooling saliva samples by 5, 10, and 20 samples prior to RNA extraction and RT-qPCR detection of SARS-CoV-2. Based on samples tested, we conservatively estimated a reduction of 7.41%, 11.11%, and 14.81% sensitivity, for each of the pool sizes, respectively. Using these estimates we modeled anticipated changes in RT-qPCR cycle threshold to show the practical impact of pooling on results of SARS-CoV-2 testing. In tested populations with greater than 3% prevalence, testing samples in pools of 5 requires the least overall number of tests. Below 1% however, pools of 10 or 20 are more beneficial and likely more supportive of ongoing surveillance strategies.

Competing Interest Statement

ALW has received research funding through grants from Pfizer to Yale and has received consulting fees for participation in advisory boards for Pfizer and PPS Health. DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax and has received research funding through grants from Pfizer to Yale.

Funding Statement

This study was funded by the Huffman Family Donor Advised Fund, Fast Grant funding support from the Emergent Ventures at the Mercatus Center, George Mason University, the Yale Institute for Global Health, Yale School of Medicine, NIAID U19 AI08992 and the Beatrice Kleinberg Neuwirth Fund. CBFV is supported by NWO Rubicon 019.181EN.004.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All study participants were enrolled and sampled in accordance to the Yale University HIC-approved protocol #2000027690. Demographics, clinical data and samples were collected after the study participant had acknowledged that they had understood the study protocol and signed the informed consent. All participant information and samples were collected in association with non-individually identifiable study identifiers. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from the corresponding author [ALW] upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted September 03, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Pooling saliva to increase SARS-CoV-2 testing capacity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pooling saliva to increase SARS-CoV-2 testing capacity
Anne E. Watkins, Eli P. Fenichel, Daniel M. Weinberger, Chantal B.F. Vogels, Doug E. Brackney, Arnau Casanovas-Massana, Melissa Campbell, John Fournier, Santos Bermejo, Rupak Datta, the Yale IMPACT Research Team, Charles S. Dela Cruz, Shelli F. Farhadian, Akiko Iwasaki, Albert I. Ko, Nathan D. Grubaugh, Anne L. Wyllie
medRxiv 2020.09.02.20183830; doi: https://doi.org/10.1101/2020.09.02.20183830
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Pooling saliva to increase SARS-CoV-2 testing capacity
Anne E. Watkins, Eli P. Fenichel, Daniel M. Weinberger, Chantal B.F. Vogels, Doug E. Brackney, Arnau Casanovas-Massana, Melissa Campbell, John Fournier, Santos Bermejo, Rupak Datta, the Yale IMPACT Research Team, Charles S. Dela Cruz, Shelli F. Farhadian, Akiko Iwasaki, Albert I. Ko, Nathan D. Grubaugh, Anne L. Wyllie
medRxiv 2020.09.02.20183830; doi: https://doi.org/10.1101/2020.09.02.20183830

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (527)
  • Epidemiology (9991)
  • Forensic Medicine (5)
  • Gastroenterology (496)
  • Genetic and Genomic Medicine (2430)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1633)
  • Health Policy (750)
  • Health Systems and Quality Improvement (632)
  • Hematology (247)
  • HIV/AIDS (529)
  • Infectious Diseases (except HIV/AIDS) (11842)
  • Intensive Care and Critical Care Medicine (623)
  • Medical Education (250)
  • Medical Ethics (73)
  • Nephrology (267)
  • Neurology (2266)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (449)
  • Occupational and Environmental Health (532)
  • Oncology (1241)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (727)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (280)
  • Psychiatry and Clinical Psychology (2272)
  • Public and Global Health (4814)
  • Radiology and Imaging (832)
  • Rehabilitation Medicine and Physical Therapy (486)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (123)
  • Urology (99)